Sangamo Therapeutics Inc (SGMO)
Official siteBIOTECHNOLOGY
Last updated: Nov 06, 2026 at 4:00 PM ET
Sangamo Therapeutics Inc (SGMO) Financials: Revenue, Profit and Cash Flow
Sangamo Therapeutics reported revenue of $39.55M for the fiscal year ended Dec 31, 2025, down 31.6% from the year before. That year, net income was -$122.93M with a net margin of -310.8%, operating cash flow was -$97.21M and free cash flow was -$97.31M. The quarter ended Mar 31, 2026 had revenue of $1.44M and net income of -$31.00M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $19.39M, a compound annual rate of 8.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $39.55M | -31.6% | 80.8% | -273.1% | -310.8% |
| Dec 2024 | $57.80M | -67.2% | 100.0% | -179.9% | -169.4% |
| Dec 2023 | $176.23M | +58.3% | 100.0% | -155.5% | -146.3% |
| Dec 2022 | $111.30M | +0.5% | 100.0% | -180.8% | -172.8% |
| Dec 2021 | $110.70M | -6.3% | 100.0% | -165.6% | -161.1% |
| Dec 2020 | $118.19M | +15.4% | 100.0% | -109.6% | -102.5% |
| Dec 2019 | $102.43M | +21.3% | 100.0% | -102.7% | -74.0% |
| Dec 2018 | $84.45M | +131.0% | 100.0% | -91.4% | -80.9% |
| Dec 2017 | $36.57M | +88.6% | 100.0% | -154.1% | -149.2% |
| Dec 2016 | $19.39M | N/A | 100.0% | -374.2% | -369.6% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.55M | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M | $102.43M | $84.45M | $36.57M | $19.39M |
| Cost of revenue | $7.60M | $9.36M | $22.19M | $12.11M | $9.44M | $180.65M | $145.92M | $114.87M | $65.73M | $65.62M |
| Gross profit | $31.95M | $57.80M | $176.23M | $111.30M | $110.70M | $118.19M | $102.43M | $84.45M | $36.57M | $19.39M |
| Research and development | $112.67M | $111.52M | $234.06M | $249.90M | $230.82M | $180.65M | $145.92M | $114.87M | $65.73M | $65.62M |
| Operating income | -$108.00M | -$103.97M | -$274.00M | -$201.28M | -$183.34M | -$129.55M | -$105.18M | -$77.15M | -$56.36M | -$72.56M |
| Net income | -$122.93M | -$97.94M | -$257.83M | -$192.28M | -$178.30M | -$121.12M | -$75.82M | -$68.33M | -$54.57M | -$71.66M |
| EBITDA | -$100.40M | -$89.09M | -$96.80M | -$180.72M | -$165.70M | -$116.18M | -$95.57M | -$74.79M | -$54.86M | -$71.56M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.44M | $14.23M | $581.00K | $18.31M | $6.44M | $7.55M | $49.41M | $356.00K | $481.00K | $2.04M | $9.40M | $6.83M |
| Gross profit | $1.44M | $14.23M | $581.00K | $18.31M | $6.44M | $7.55M | $49.41M | $356.00K | $481.00K | $2.04M | -$47.69M | -$52.41M |
| Operating income | -$31.95M | -$24.97M | -$35.55M | -$17.86M | -$29.63M | -$25.99M | $10.63M | -$37.08M | -$51.53M | -$62.06M | -$106.41M | -$123.57M |
| Net income | -$31.00M | -$37.42M | -$34.93M | -$19.99M | -$30.60M | -$23.40M | $10.67M | -$36.13M | -$49.09M | -$60.30M | -$104.16M | -$114.51M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $1.70M by $19.25M. Shareholder equity was negative, at -$14.27M, as total liabilities of $74.01M exceeded total assets of $59.74M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $59.74M | $101.64M | $165.32M | $562.51M | $721.92M | $938.55M | $637.52M | $590.39M | $286.74M | $157.89M |
| Current assets | $35.83M | $51.69M | $94.33M | $300.33M | $398.77M | $659.67M | $405.47M | $410.52M | $248.40M | $149.58M |
| Cash and equivalents | $20.95M | $41.92M | $45.20M | $100.44M | $178.87M | $131.33M | $80.43M | $140.42M | $49.83M | $22.06M |
| Total liabilities | $74.01M | $78.86M | $82.43M | $267.55M | $346.58M | $441.18M | $204.78M | $223.88M | $98.84M | $21.70M |
| Short-term debt | $1.70M | $4.31M | $4.59M | $4.12M | $4.03M | $3.69M | $3.21M | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $24.74M | $3.94M |
| Shareholder equity | -$14.27M | $22.77M | $82.89M | $294.96M | $375.34M | $498.23M | $432.55M | $366.52M | $187.90M | $136.19M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $59.97M | $59.74M | $88.64M | $97.56M | $86.17M | $101.64M | $111.26M | $93.01M | $128.96M | $165.32M | $219.70M | $325.07M |
| Total liabilities | $78.92M | $74.01M | $82.40M | $77.96M | $81.26M | $78.86M | $72.13M | $69.32M | $72.26M | $82.43M | $84.78M | $91.43M |
| Cash and equivalents | $27.59M | $20.95M | $30.53M | $38.34M | $25.18M | $41.92M | $39.20M | $27.79M | $54.42M | $45.20M | $56.51M | $66.83M |
| Shareholder equity | -$18.95M | -$14.27M | $6.24M | $19.60M | $4.91M | $22.77M | $39.13M | $23.69M | $56.70M | $82.89M | $134.92M | $233.64M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$97.21M | -$67.14M | -$224.84M | -$223.63M | -$233.25M | $169.88M | -$144.40M | $37.15M | $11.18M | -$65.88M |
| Capital expenditures | $102.00K | $267.00K | $21.16M | $20.17M | $23.28M | $14.71M | $20.68M | $43.06M | $3.75M | $732.00K |
| Free cash flow | -$97.31M | -$67.41M | -$246.00M | -$243.80M | -$256.53M | $155.16M | -$165.08M | -$5.91M | $7.43M | -$66.61M |
| Investing cash flow | -$102.00K | $37.52M | $153.53M | $59.28M | $248.20M | -$271.63M | -$59.80M | -$178.11M | -$80.90M | $18.13M |
| Financing cash flow | $70.75M | $28.38M | $14.59M | $84.66M | $32.86M | $153.10M | $142.03M | $231.71M | $97.49M | $337.00K |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.28M | -$24.40M | -$28.50M | -$18.16M | -$26.15M | -$3.35M | $11.76M | -$26.88M | -$48.66M | -$50.54M | -$47.29M | -$60.71M |
| Capital expenditures | $13.00K | $14.00K | $64.00K | $24.00K | $0 | $152.00K | $115.00K | $0 | $0 | $2.67M | $2.74M | $5.54M |
| Free cash flow | -$19.30M | -$24.42M | -$28.56M | -$18.18M | -$26.15M | -$3.50M | $11.64M | -$26.88M | -$48.66M | -$53.21M | -$50.04M | -$66.25M |
Frequently Asked Questions About SGMO
What is Sangamo Therapeutics' annual revenue?
Sangamo Therapeutics reported revenue of $39.55M for the fiscal year ended Dec 31, 2025.
How fast is Sangamo Therapeutics' revenue growing?
Revenue was down 31.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -29.2%.
Is Sangamo Therapeutics profitable?
No. Sangamo Therapeutics reported net income of -$122.93M for the fiscal year ended Dec 31, 2025, with a net margin of -310.8%.
How much free cash flow does SGMO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$97.21M minus capital expenditures of $102.00K produced free cash flow of -$97.31M.
How much debt does Sangamo Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.70M and cash and equivalents of $20.95M.
SGMO pages: Overview, Financials